Seeing Is Believing
Currently out of the existing stock ratings of David Nierengarten, 312 are a BUY (82.98%), 62 are a HOLD (16.49%), 2 are a SELL (0.53%).
Analyst David Nierengarten, currently employed at WEDBUSH, carries an average stock price target met ratio of 42.29% that have a potential upside of 43.87% achieved within 199 days.
David Nierengarten’s has documented 826 price targets and ratings displayed on 64 stocks. The coverage is on Healthcare, Communication Services, Technology sectors.
Most recent stock forecast was given on VOR, Vor Biopharma at 26-Jun-2025.
Analyst best performing recommendations are on SRRK (SCHOLAR ROCK HOLDING CORP).
The best stock recommendation documented was for SRRK (SCHOLAR ROCK HOLDING CORP) at 6/18/2018. The price target of $25 was fulfilled within 1 day with a profit of $3.57 (16.66%) receiving and performance score of 166.59.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$38
$11.8 (45.04%)
$22
1 months 11 days ago
(03-Jun-2025)
3/9 (33.33%)
$16.73 (78.66%)
44
Buy
$90
$63.8 (243.51%)
$54
1 months 17 days ago
(27-May-2025)
2/11 (18.18%)
$69.1 (330.62%)
229
Buy
$42
$15.8 (60.31%)
$36
4 months 10 days ago
(04-Mar-2025)
7/13 (53.85%)
$25.3 (151.50%)
545
Buy
$40
$13.8 (52.67%)
$42
5 months 8 days ago
(06-Feb-2025)
11/18 (61.11%)
$25.42 (174.35%)
108
Hold
$18
$-8.2 (-31.30%)
$33
7 months 2 days ago
(12-Dec-2024)
5/11 (45.45%)
$2.41 (15.46%)
109
Which stock is David Nierengarten is most bullish on?
Which stock is David Nierengarten is most reserved on?
What Year was the first public recommendation made by David Nierengarten?